Related Experiment Videos
Cardiac Resynchronization Therapy for Advanced Heart Failure
Philip B. Adamson1, William T. Abraham
1Departments of Medicine, Cardiology, and Physiology, University of Oklahoma Health Sciences Center, P.O. Box 26901, 920 S.L. Young Boulevard, WP3120, Oklahoma City, OK 73190, USA. Philip-adamson@ouhsc.edu
Insights
Cardiac resynchronization therapy (CRT) improves heart failure outcomes. Refining patient selection criteria is crucial to maximize benefits and minimize nonresponse rates for this device-based therapy.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Cardiac resynchronization therapy (CRT) offers symptom relief and reduces hospitalizations for advanced heart failure patients.
- Current CRT candidates include patients with dilated cardiomyopathy and conduction delays (NYHA class III-IV).
- CRT can reverse ventricular remodeling, reduce mitral regurgitation, and improve cardiac efficiency.
Purpose of the Study:
- To review current strategies for refining patient selection criteria for CRT.
- To identify patient subgroups likely to respond or not respond to CRT.
- To address practical considerations in prescribing CRT.
Main Methods:
- Review of existing literature and clinical guidelines on CRT patient selection.
- Analysis of factors influencing CRT response rates.
- Discussion of evolving criteria for CRT candidacy.
Main Results:
- A significant percentage of patients (20-25%) do not respond to current CRT selection criteria.
- New criteria are being explored to improve patient selection and outcomes.
- Potential benefits of CRT extend to patients needing pacing, with atrial fibrillation, or prophylactic defibrillators.
Conclusions:
- Optimizing patient selection is key to improving CRT efficacy.
- Further research is needed to refine CRT prescribing practices.
- CRT remains a vital therapy for selected heart failure patients.
Abstract:
Cardiac resynchronization therapy (CRT) represents a new class of heart failure therapy that provides symptom relief and decreased need of hospitalization in a significant number of patients already receiving maximal medical intervention. Patients with ischemic or nonischemic dilated cardiomyopathy, coupled with interventricular conduction delays, who have New York Heart Association class III or IV symptoms, are currently candidates for CRT. This device-based intervention reverses adverse ventricular remodeling, decreases the severity of mitral regurgitation, and increases cardiac efficiency and output. New selection criteria are being considered in an attempt to identify patients who have a high chance of responding, and possibly, to identify patients that have a high chance of not responding to CRT. These efforts are in response to the 20% to 25% "nonresponder" rate observed when the currently accepted inclusion criteria are used. Other patient populations may also benefit from CRT, including those in need of antibradycardia pacing, patients with atrial fibrillation, and some who meet the criteria for prophylactic implantation of a cardiac defibrillator. This review focuses on the current strategies to refine patient selection criteria and addresses some of the practical issues in prescribing CRT.